Experts Say Treatment Experimental, Expensive and Possibly Effective

"It shrinks tumors in about a third of cases significantly, and it lasts on average about two to three years," said Strosberg."Even though you get tumor shrinkage, you mostly get disease progression that stabilizes," said Dr. Thomas O'Dorisio, professor of medicine at the University of Iowa in Iowa City. Experts believe the FDA will eventually approve PRRT.

"The data are coming out slowly. There's never been a phase 3 clinical trial, and that's why it's not okayed yet," said O'Dorisio. "It's a new, experimental treatment, and it has to go through the same approval process as all drugs," said Ayala.

From ABC News